vs
Circle Internet Group, Inc.(CRCL)与Royalty Pharma plc(RPRX)财务数据对比。点击上方公司名可切换其他公司
Circle Internet Group, Inc.的季度营收约是Royalty Pharma plc的1.2倍($739.8M vs $622.0M),Royalty Pharma plc净利率更高(34.4% vs 29.0%,领先5.5%),Circle Internet Group, Inc.同比增速更快(5113.5% vs 4.8%)
Circle是2013年由杰里米·阿莱尔与肖恩·内维尔联合创立的支付科技企业,目前总部位于美国纽约,核心业务覆盖稳定币发行,推出了锚定美元的USDC、锚定欧元的EURC两款稳定币,同时还发行有代币化货币市场基金产品USYC。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业,专注于研发可调节转化生长因子β(TGF-β)超家族蛋白的药物,该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CRCL vs RPRX — 直观对比
营收规模更大
CRCL
是对方的1.2倍
$622.0M
营收增速更快
CRCL
高出5108.8%
4.8%
净利率更高
RPRX
高出5.5%
29.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $739.8M | $622.0M |
| 净利润 | $214.4M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 11.0% | 62.4% |
| 净利率 | 29.0% | 34.4% |
| 营收同比 | 5113.5% | 4.8% |
| 净利润同比 | 202.0% | 2.9% |
| 每股收益(稀释后) | $0.64 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
CRCL
RPRX
| Q4 25 | — | $622.0M | ||
| Q3 25 | $739.8M | $609.3M | ||
| Q2 25 | $658.1M | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | — | $593.6M | ||
| Q3 24 | — | $564.7M | ||
| Q2 24 | $6.8M | $537.3M | ||
| Q1 24 | — | $568.0M |
净利润
CRCL
RPRX
| Q4 25 | — | $214.2M | ||
| Q3 25 | $214.4M | $288.2M | ||
| Q2 25 | $-482.1M | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | — | $544.0M | ||
| Q2 24 | $32.9M | $102.0M | ||
| Q1 24 | — | $4.8M |
营业利润率
CRCL
RPRX
| Q4 25 | — | 62.4% | ||
| Q3 25 | 11.0% | 70.1% | ||
| Q2 25 | -49.5% | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 50.2% | ||
| Q1 24 | — | -13.0% |
净利率
CRCL
RPRX
| Q4 25 | — | 34.4% | ||
| Q3 25 | 29.0% | 47.3% | ||
| Q2 25 | -73.3% | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | — | 96.3% | ||
| Q2 24 | 486.5% | 19.0% | ||
| Q1 24 | — | 0.8% |
每股收益(稀释后)
CRCL
RPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | $0.64 | $0.67 | ||
| Q2 25 | $-4.48 | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | — | $1.21 | ||
| Q2 24 | $0.00 | $0.23 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $3.0B | $9.7B |
| 总资产 | $76.8B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势,按日历期对齐
现金及短期投资
CRCL
RPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | $1.3B | $938.9M | ||
| Q2 25 | $1.1B | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | $457.5M | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务
CRCL
RPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益
CRCL
RPRX
| Q4 25 | — | $9.7B | ||
| Q3 25 | $3.0B | $9.6B | ||
| Q2 25 | $2.4B | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | — | $10.3B | ||
| Q3 24 | — | $10.3B | ||
| Q2 24 | $460.9M | $9.8B | ||
| Q1 24 | — | $9.9B |
总资产
CRCL
RPRX
| Q4 25 | — | $19.6B | ||
| Q3 25 | $76.8B | $19.3B | ||
| Q2 25 | $64.2B | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | — | $18.2B | ||
| Q3 24 | — | $18.0B | ||
| Q2 24 | — | $17.7B | ||
| Q1 24 | — | $16.1B |
负债/权益比
CRCL
RPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-10.7M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.7M | — |
| 自由现金流率自由现金流/营收 | -2.0% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | -0.05× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势,按日历期对齐
经营现金流
CRCL
RPRX
| Q4 25 | — | $827.1M | ||
| Q3 25 | $-10.7M | $702.6M | ||
| Q2 25 | $303.7M | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | — | $742.5M | ||
| Q3 24 | — | $703.6M | ||
| Q2 24 | — | $658.2M | ||
| Q1 24 | — | $664.6M |
自由现金流
CRCL
RPRX
| Q4 25 | — | — | ||
| Q3 25 | $-14.7M | — | ||
| Q2 25 | $296.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率
CRCL
RPRX
| Q4 25 | — | — | ||
| Q3 25 | -2.0% | — | ||
| Q2 25 | 45.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度
CRCL
RPRX
| Q4 25 | — | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率
CRCL
RPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | -0.05× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRCL
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |